BMO Expands Canadian Depositary Receipt Lineup with 10 New Listings from Europe and Japan

BMO's CDRs offer enhanced portfolio diversification opportunities for Canadian investors enabling them to hold shares in international companies that trade on a Canadian exchange in Canadian dollars

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

BMO's new CDRs will trade under the following tickers:

Company Name

CDR Ticker

Jurisdiction

Novo Nordisk A/S

NOVE

Denmark

SAP SE

SAPG

Germany

ASML Holding NV

ASMH

Netherlands

CIE Financiere Richemont AG

RCHM

Switzerland

Novartis AG

NOVN

Switzerland

Roche Holdings AG

ROCH

Switzerland

UBS Group AG

UBS

Switzerland

Mitsubishi Corp.

MTSU

Japan

Mitsubishi UFJ Financial Group

MUFG

Japan

Softbank Group Corp.

SFTB

Japan

For more information on BMO's CDRs, please visit www.bmocdrs.com .

This material is for information purposes only. The information contained herein is not, and should not be construed as, investment, tax or legal advice to any party.

An investment in CDRs issued by BMO may not be suitable for all investors. Important information about these investment products is contained in the short form base shelf prospectus and prospectus supplement for each series of CDRs (together, the " Prospectus "). Purchasers are directed to www.sedarplus.ca or to www.bmogam.com to obtain copies of the Prospectus and related disclosure before purchasing CDRs of a particular series. The information contained herein is not a recommendation to purchase these investment products.

Each series of CDRs relates to a single class of equity securities (the " Underlying Shares ") of an issuer incorporated outside of Canada (the " Underlying Issuer "). For each series of CDRs, the Prospectus will provide additional information regarding such series, including information regarding the Underlying Issuer and Underlying Shares for such series. Neither BMO and its affiliates nor any other person involved in the distribution of CDRs accepts any responsibility for any disclosure provided by any Underlying Issuer (including information contained herein or in the Prospectus that has been extracted from any Underlying Issuer's publicly disseminated disclosure). Each series of CDRs is only offered to investors in Canada in accordance with applicable laws and regulatory requirements.

"BMO (M-bar roundel symbol)" is a registered trademark of Bank of Montreal , used under licence.

About BMO Financial Group

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.41 trillion as of October 31, 2024. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States , and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life , BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.

SOURCE BMO Financial Group

News Provided by PR Newswire via QuoteMedia

NVS
The Conversation (0)
Excalibur Metals Plans Property-Wide Exploration Program at Bellehelen Silver-Gold Project and Announces Director Nominees

Excalibur Metals Plans Property-Wide Exploration Program at Bellehelen Silver-Gold Project and Announces Director Nominees

Excalibur Metals Corp. (TSXV: EXCL,OTC:EXCBF) (OTCQB: EXCBF) ("Excalibur" or the "Company") is pleased to announce plans for an extensive follow-up field exploration program (the "Program") at its Bellehelen Silver-Gold Project ("Bellehelen" or the "Project") in Nye County, Nevada.The planned... Keep Reading...
Metalsource Mining Intersects High Grade Silver Hill Mineralization to 335 Metres Below Surface with 55 Metre Down Plunge Step Outs

Metalsource Mining Intersects High Grade Silver Hill Mineralization to 335 Metres Below Surface with 55 Metre Down Plunge Step Outs

55 metre away down plunge drilling step out returns multiple intervals within mineralized zones up to 15.3 metres wide as drilling continues to expand known mineralization and refine targeting toward higher grade zones. Metalsource Mining Inc. (CSE: MSM,OTC:MSMMF) (OTCQB: MSMMF) (FSE: E9Z)... Keep Reading...
Excalibur Metals Defines New Silver-Gold Soil Anomalies North of Spyglass Ridge

Excalibur Metals Defines New Silver-Gold Soil Anomalies North of Spyglass Ridge

Excalibur Metals Corp. (TSXV: EXCL,OTC:EXCBF) (OTCQB: EXCBF) ("Excalibur" or the "Company") is pleased to announce results from expanded soil sampling north of the Spyglass Ridge Target ("Spyglass Ridge") at its Bellehelen Silver-Gold Project ("Bellehelen" or the "Project") in Nye County,... Keep Reading...
Metalsource Mining Launches Expansion Drilling Near Highest Grade Intercept at Silver Hill

Metalsource Mining Launches Expansion Drilling Near Highest Grade Intercept at Silver Hill

New drilling will target strike and down plunge extensions of the exceptional polymetallic mineralization intersected in Hole SH26-07 as the Company's second drill rig prepares to evaluate newly identified district scale exploration targets.Metalsource Mining Inc. (CSE: MSM,OTC:MSMMF) (OTCQB:... Keep Reading...
Metalsource Mining Extends Strike Length of Mineralization at Silver Hill with 65m South Step Out from SH26-19

Metalsource Mining Extends Strike Length of Mineralization at Silver Hill with 65m South Step Out from SH26-19

Hole SH26-27 identifies approximately 15 metres (core length) of mineralization, representing the largest southern step out completed to date and extending the known Silver Hill system approximately 65 metres beyond Hole SH26-19. Metalsource Mining Inc. (CSE: MSM,OTC:MSMMF) (OTCQB: MSMMF) (FSE:... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...

Interactive Chart

Latest Press Releases

Related News